Fig 1.
Participant flowchart of the trial.
Table 1.
Baseline characteristics of participants in each group.
Fig 2.
Effect of UB0316 and placebo on primary and secondary end points change (%) from baseline value (adjusted to zero) to week 12.
HbA1c: glycated hemoglobin; FBG: fasting blood glucose; HOMA-IR: homeostatic model assessment of insulin resistance; TC: total cholesterol; TG: triglycerides; HDL: high density lipoproteins; LDL: low density lipoproteins. The percent change was calculated as, Mean week 12 –Mean baseline / Mean baseline × 100.
Table 2.
Primary and secondary outcomes (baseline to week 12) of the Intention-to-Treat and Per Protocol populations.
Fig 3.
Effect of UB0316 and placebo on quality of life change (%) from baseline value (adjusted to zero) to week 4, 8 and 12.
The percent change was calculated as, Mean week−Mean baseline / Mean baseline × 100.
Table 3.
Quality of life assessment of the Intention-to-Treat and Per Protocol populations.